Results 31 to 40 of about 7,748 (215)
Novel Chemokine-Based Immunotoxins for Potent and Selective Targeting of Cytomegalovirus Infected Cells [PDF]
, 2017 Immunotoxins as antiviral therapeutics are largely unexplored but have promising prospective due to their high selectivity potential and their unparalleled efficiency.
Jeppesen, Mads G. +5 more
core +5 more sources
Treatment with immunotoxin [PDF]
Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 2001 T–cell depletion prior to or beginning at the time of transplantation has been shown to be a valuable adjunct to the induction of immunological unresponsiveness. Both total lymphoid irradiation and anti–lymphocyte globulin have been used for this purpose in experimental models of transplantation as well as in human organ transplant recipients. However,
openaire +2 more sources
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components [PDF]
, 2011 Immunotoxins and antibody-drug conjugates are protein-based drugs combining a target-specific binding domain with a cytotoxic domain. Such compounds are potentially therapeutic against diseases including cancer, and several clinical trials have shown ...
Franco Dosio, Luigi Cattel, Paola Brusa
core +3 more sources
Immunotoxin: A new tool for cancer therapy
Tumor Biology, 2017 Cancer is one of the main reasons of death in the most countries and in Iran. Immunotherapy quickly became one of the best methods of cancer treatment, along with chemotherapy and radiation. “Immunotoxin Therapy” is a promising way of cancer therapy that
Hossein Allahyari +4 more
doaj +1 more source
B‐cell receptors of EBV‐negative Burkitt lymphoma bind modified isoforms of autoantigens
eJHaem, 2022 Burkitt lymphoma (BL) represents the most aggressive B‐cell‐lymphoma. Beside the hallmark of IG‐MYC‐translocation, surface B‐cell receptor (BCR) is expressed, and mutations in the BCR pathway are frequent.
Theresa Bock +24 more
doaj +1 more source
Nanobody based dual specific CARs [PDF]
, 2018 Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich +8 more
core +2 more sources
Saporin-S6: A Useful Tool in Cancer Therapy
Toxins, 2013 Thirty years ago, the type 1 ribosome-inactivating protein (RIP) saporin-S6 (also known as saporin) was isolated from Saponaria officinalis L. seeds. Since then, the properties and mechanisms of action of saporin-S6 have been well characterized, and it ...
Letizia Polito +4 more
doaj +1 more source
Antibodies, 2014 Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will reduce major side effects accompanied with conventional treatment modalities. The immunotoxin concept uses bacterial or plant toxins, coupled to antibodies
Nina Berges +5 more
doaj +1 more source
GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. [PDF]
, 2014 The emergence of targeted cancer therapy has been limited by the paucity of determinants which are tumor-specific and generally associated with disease, and have cell dynamics which effectively deploy cytotoxic payloads.
Berman-Booty, Lisa D +5 more
core +3 more sources
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
Toxins, 2016 Many epithelial cancers rely on enhanced expression of the epidermal growth factor receptor (EGFR) to drive proliferation and survival pathways. Development of therapeutics to target EGFR signaling has been of high importance, and multiple examples have ...
Nathan Simon, David FitzGerald
doaj +1 more source